Inhaltsbereich
| 10 Einträge |
Seite 1 / 1
 Druckansicht
|
| Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. |
| von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J |
| The Lancet. Oncology. 2014 Sep 28. pii: S1470-2045(14)70439-5. doi: 10.1016/S1470-2045(14)70439-5 |
| PMID: 25273342 |
| Endocrine therapy plus zoledronic acid in premenopausal breast cancer. |
| Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, Marth C |
| The New England journal of medicine. 2009 Feb 13. pii: 360/7/679. doi: 10.1056/NEJMoa0806285 |
| PMID: 19213681 |
| Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. |
| Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2003 Nov 21. |
| PMID: 14630678 |
| Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. |
| Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016 Aug 8. pii: mdw316. doi: 10.1093/annonc/mdw316 |
| PMID: 27502725 |
| Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). |
| Díaz-Rubio E, Burris H, Douillard JY, Coxon FY, Maughan T, Bertetto O, Schueller J, Husseini F, Marschner N, Scheithauer W |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Jan 1. pii: 10.1200/jco.2004.22.14_suppl.3737 |
| PMID: 28013721 |
| 353OEFFICACY AND SAFETY IN TANIA, A RANDOMISED PHASE III TRIAL OF CONTINUED OR REINTRODUCED BEVACIZUMAB (BEV) AFTER 1ST-LINE BEV FOR HER2-NEGATIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC). |
| von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva CB, Romieu G, Láng I, Ciruelos E, De Laurentiis M, Veyret C, De Ducla S, Freudensprung U, Srock S, Gligorov J |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Feb 7. pii: 2241122. doi: 10.1093/annonc/mdu329.3 |
| PMID: 28171246 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
| The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
| PMID: 29146401 |
| Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. |
| Schmidt M, Rüttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA, Wolf A, Göppel G, Oruzio D, Schlimok G, Steger GG, Wolf C, Eiermann W, Lang A, Schuler M |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Dec 4. pii: S0923-7534(19)35195-6. doi: 10.1093/annonc/mdr625 |
| PMID: 32018702 |
| An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. |
| Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M, Rüttinger D, Schuler M, Reinhardt C, Awada A |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Jul 24. pii: S0923-7534(19)38761-7. doi: 10.1093/annonc/mdp314 |
| PMID: 19633042 |
| Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. |
| Schmidt M, Rüttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA, Wolf A, Göppel G, Oruzio D, Schlimok G, Steger GG, Wolf C, Eiermann W, Lang A, Schuler M |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Feb 21. pii: S0923-7534(19)35195-6. doi: 10.1093/annonc/mdr625 |
| PMID: 22357251 |
| 10 Einträge |
Seite 1 / 1
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
